Short answer
Nuvectis Pharma, Inc. (NVCT) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results and corporate update announced for quarter ended March 31, 2026.
Nuvectis Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results and corporate update announced for quarter ended March 31, 2026
- Detailed results and management commentary provided in Exhibit 99.1 press release
- Information furnished under Regulation FD, not filed under Exchange Act Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $6.1M versus $5.3M, reflecting continued investment ahead of clinical milestones
- Cash $25.1M at March 31, 2026 versus $31.6M year-end, highlighting ongoing funding and dilution risk
- Shares outstanding rose to 26.5M from 25.7M, indicating equity issuance during the quarter
- NXP900 Phase 1b continues enrolling in monotherapy and combination arms across US sites
- Preliminary NXP900 Phase 1b data expected in summer 2026, a key near-term catalyst for NVCT valuation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvectis Pharma, Inc. 8-K filings
Get the next NVCT 8-K as it lands
Follow NVCT for push alerts, or ask the research agent what this filing means.